Start the conversation
When we first recommended this stock back in early February of last year (and in subsequent follow-on reports), we based our "call" on the fact that the company:
- Has great science.
- Is targeting a market with a huge need.
- And could end up either partnering with a Big Pharma player, or being "taken out" in a lucrative (for you) buyout transaction.
This is one recommendation that's worked out even better than we expected - all because of the three potential catalysts we identified...
This is premium content for Private Briefing subscribers only.